Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Human Specific Hyperimmune Globulins (HIG) are dosage forms of the concentrated purified protein fraction of immunoglobulin G against a specific viral or bacterial antigen. Effective and safe methods of the antibody’s purification makes possible to consider HIG as a preventive and curative agent, for the viral infections, against which there is no specific preventive or antiviral therapy, as well as bacterial infectious diseases due to increasing resistance to antibacterial drugs, especially in persons with immunodeficiencies.

Full Text

Restricted Access

About the authors

Т. А. Igityan

Peoples’ Friendship University of Russia named after Patrice Lumumba

Email: olgaburgasova@mail.ru
ORCID iD: 0009-0000-4257-3243
Russian Federation, Moscow

О. А. Burgasova

Peoples’ Friendship University of Russia named after Patrice Lumumba; National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: olgaburgasova@mail.ru
ORCID iD: 0000-0002-5486-0837

Professor, MD

Russian Federation, Moscow; Moscow

L. V. Generalova

Peoples’ Friendship University of Russia named after Patrice Lumumba

Author for correspondence.
Email: olgaburgasova@mail.ru
ORCID iD: 0000-0001-9433-2468

Candidate of Medical Sciences

Russian Federation, Moscow

References

  1. Katragkou A., Roilides E., Walsh T. J. Role of immunoglobulin therapy to prevent and treat infections. Management of Infections in the Immunocompromised Host. 2018; 339–58. doi: 10.1007/978-3-319-77674-3_17
  2. Winau F., Winau R. Emil von Behring and serum therapy. Microbes Infect. 2002; 4 (2): 185–8. doi: 10.1016/s1286-4579(01)01526-x
  3. Graham B.S., Ambrosino D.M. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015; 10 (3): 129. doi: 10.1097/COH.0000000000000154
  4. Заплатников А.Л. Специфические иммуноглобулины для внутривенного введения в педиатрической практике. Педиатрическая фармакология. 2007; 4 (1): 48–50 [Zaplatnikov A. Specific immunoglobulins for intravenous injection in pediatric practices. Pediatric pharmacology. 2007; 4 (1): 48–50 (in Russ.)].
  5. Casadevall A., Scharff M. D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994; 38 (8): 1695–702. doi: 10.1128/aac.38.8.1695
  6. Casadevall A., Scharff M. D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995; 21 (1): 150–61. doi: 10.1093/clinids/21.1.150
  7. Pati I., Cruciani M., Candura F. et al. Hyperimmune Globulins for the Management of Infectious Diseases. Viruses. 2023; 15 (7): 1543. doi: 10.3390/v15071543
  8. Василев Ч.Л., Старкина О.В. Иммуноглобулины человека как иммуномодулирующие препараты. Молекулярная биология. 2019; 53 (5): 860–70 [Vassilev T.L., Starkina O.V. Pooled Human Immunoglobulin Preparations as Immunomodulating Drugs. Molecular Biology. 2019; 53 (5): 860–70 (in Russ.)] doi: 10.1134/S0026893319050145
  9. Супотницкий М.В., Елапов А.А., Борисевич И.В. и др. Препараты крови человека и животных в аспекте показателей качества, эффективности и безопасности. БИОпрепараты. Профилактика, диагностика, лечение. 2015; 3: 33–48 [Supotnitsky M.V., Elapov A.A., Borisevich I.V. et al. Blood preparations of humans and animals in terms of their quality, efficacy and safety. BIOpreparations. Prevention, Diagnosis, Treatment. 2015; 3: 33–48 (in Russ.)].
  10. Донюш Е.К. Использование внутривенных иммуноглобулинов в клинической практике. Вопросы современной педиатрии. 2011; 10 (2): 49–63 [Donyush E. Use of intravenous immunoglobulins in clinical practice. Current Pediatrics. 2011; 10 (2): 49–63 (in Russ.)].
  11. Борисевич И.В., Кудашева Э.Ю., Иванов В.Б. и др. Препараты иммуноглобулинов человека специфические для лечения и профилактики инфекционных заболеваний. Иммунология. 2017; 38 (6): 320–6 [Borisevich I.V., Kudasheva E.Yu., Ivanov V.B. et al. Specific human immunoglobulin preparations for treatment and prevention of infectious diseases. Immunologiya. 2017; 38 (6): 320–6 (in Russ.)] doi: 10.18821/0206-4952-2017-38-6-320-326
  12. Luke T.C., Kilbane E.M., Jackson J.L. et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145 (8): 599–609. doi: 10.7326/0003-4819-145-8-200610170-00139
  13. Арутюнов А.Г., Авдеев С.Н., Батюшин М.М. и др. Применение КОВИД-глобулина в терапии COVID-19. Экспериментальная и клиническая фармакология. 2022; 85 (3): 13–20 [Arutyunov A.G., Avdeev S.N., Batyushin M.M. et al. Using COVID-globulin in COVID-19 treatment. Experimental and Clinical Pharmacology. 2022; 85 (3): 13–20 (in Russ.)]. doi: 10.30906/0869-2092-2022-85-3-13-20
  14. Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol. 2009; 158 (Suppl 1): 2–13. doi: 10.1111/j.1365-2249.2009.04022.x
  15. Антонов А.Г., Ашиткова Н.В., Бирюкова Т.В. и др. Формуляр по использованию препаратов иммуноглобулинов для внутривенного введения в неонатологии. Вопросы практической педиатрии. 2007; 2 (2): 56–65 [Antonov A.G., Ashitkova N.V., Biryukova T.V. Formulary of administration of intravenous immune globulins in neonatology. Clinical Practice in Pediatrics. 2007; 2 (2): 56–65 (In Russ)]
  16. Государственная фармакопея Российской Федерации. 14-е изд. Т.4. М.; 2018 [Gosudarstvennaya farmakopeya Rossiiskoi Federatsii. 14-e izd. Vol. 4. M., 2018 (in Russ.)]. URL: https://femb.ru/record/pharmacopea14
  17. Иммуноглобулин человека нормальный для внутривенного введения: ФС.3.3.2.0008.15. Государственная фармакопея Российской Федерации ХIII изд. Т. III [Immunoglobulin cheloveka normal'nyi dlya vnutrivennogo vvedeniya: FS.3.3.2.0008.15. Gosudarstvennaya farmakopeya Rossiiskoi Federatsii KhIII izd. T. III. (in Russ.)]. URL: https://pharmacopoeia.ru/fs-3-3-2-0008-15-immunoglobulin-cheloveka-normalnyj-dlya-vnutrivennogo-vvedeniya/?ysclid=ltefuz68dn811698960
  18. Волкова Р.А., Фадейкина О.В., Климов В.И. и др. Актуальные вопросы стандартных образцов в сфере обращения биологических лекарственных средств. БИОпрепараты. Профилактика, диагностика, лечение. 2016; 16 (4): 229–36 [Volkova R.A., Fadeikina O.V., Klimov V.I., et al. Topical issues related to reference standards in the sphere of circulation of biological products. BIOpreparations. Prevention, Diagnosis, Treatment. 2016; 16 (4): 229–36 (in Russ.)].
  19. Организация и проведение серологического мониторинга состояния коллективного иммунитета к инфекциям, управляемым средствами специфической профилактики (дифтерия, столбняк, коклюш, корь, краснуха, эпидемический паротит, полиомиелит, ВГВ): Методические указания. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2011; 19 с. [Organizatsiya i provedenie serologicheskogo monitoringa sostoyaniya kollektivnogo immuniteta k infektsiyam, upravlyaemym sredstvami spetsificheskoi profilaktiki (difteriya, stolbnyak, koklyush, kor', krasnukha, epidemicheskii parotit, poliomielit, gepatit V): Metodicheskie ukazaniya. M.: Federal'nyi tsentr gigieny i epidemiologii Rospotrebnadzora, 2011, 19 р. (in Russ.)].
  20. Cristiano A., Nuccetelli M., Pieri M. et al. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. Int Immunopharmacol. 2021; 101: 108215. doi: 10.1016/j.intimp.2021.108215
  21. Пеньевская Н.А., Злобин В.И. Экстренная профилактика клещевого энцефалита с помощью гомологичного специфического иммуноглобулина: теория и практика. Эпидемиология и вакцинопрофилактика. 2013; 3 (70): 81–9 [Pen'evskaya N.A., Zlobin V.I. Emergency prevention of tick-borne encephalitis virus by homologous specific immunoglobulin: theory and practice. Epidemiologiya i vaktsinoprofilaktika. 2013; 3 (70): 81–9 (in Russ.)].
  22. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211 (1): 80–90. doi: 10.1093/infdis/jiu396
  23. Государственный реестр лекарственных средств Министерства здравоохранения Российской Федерации [Gosudarstvennyj reestr lekarstvennyh sredstv Ministerstva zdravoohranenija Rossijskoj Federacii (in Russ.)]. URL: http://grls.rosminzdrav.ru/grls.aspx
  24. Bonaros N., Mayer B., Schachner T. et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008; 22 (1): 89–97. doi: 10.1111/j.1399-0012.2007.00750.x
  25. Barten M.J., Baldanti F., Staus A. et al. Effectiveness of prophylactic human cytomegalovirus hyperimmunoglobulin in preventing cytomegalovirus infection following transplantation: a systematic review and meta-analysis. Life (Basel). 2022; 12 (3): 361. doi: 10.3390/life12030361
  26. Shi Z., Li X., Ma L. et al. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission – a meta-analysis. Int J Infect Dis. 2010; 14 (7): e622-e634. doi: 10.1016/j.ijid.2009.09.008
  27. Wang P., Tam N., Wang H. et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One. 2014; 9 (8): e104480. doi: 10.1371/journal.pone.0104480
  28. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 2023 (in Russ.)]. URL: https://coronavirus.jhu.edu/map.html
  29. Parikh D., Chaturvedi A., Shah N. et al. Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection-Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial. medRxiv. 2021. doi: 10.1101/2021.07.26.21261119
  30. Cagdas D. Convalescent plasma and hyperimmune globulin therapy in COVID-19. Expert Rev Clin Immunol. 2021; 17 (4): 309–16. doi: 10.1080/1744666X.2021.1894927
  31. Nguyen A.A., Habiballah S.B., Platt C.D. et al. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clin Immunol. 2020; 216: 108459. doi: 10.1016/j.clim.2020.108459
  32. Смолянова Т.И., Багаева Н.С., Колганова М.А. и др. Изучение фармакокинетики препарата «КОВИД-глобулин» (специфический иммуноглобулин человека против COVID-19) (АО «Нацимбио», Россия) в рамках фазы I клинического исследования. Разработка и регистрация лекарственных средств. 2022; 11 (2): 180–6 [Smolyanova T.I., Bagaeva N.S., Kolganova M.A. et al. Phase I Pharmacokinetics Study of Drug «COVID-globulin» (Specific Human Immunoglobulin Against COVID-19). Drug development & registration. 2022; 11 (2): 180–6 (in Russ.)] doi: 10.33380/2305-2066-2022-11-2-180-186
  33. Takada A., Feldmann H., Ksiazek T.G. et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003; 77 (13): 7539–44. doi: 10.1128/JVI.77.13.7539-7544.2003
  34. Kliks S.C., Nisalak A., Brandt W.E. et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989; 40 (4): 444–51. doi: 10.4269/ajtmh.1989.40.444
  35. Hung I.F.N., To K.K.W., Lee C.-K. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest. 2013; 144 (2): 464–73. doi: 10.1378/chest.12-2907
  36. Davey R.T., Fernández-Cruz E., Markowitz N. et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019; 7 (11): 951–63. doi: 10.1016/S2213-2600(19)30253-X

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Mechanisms of SARS-CoV-2 virus neutralization by using hyperimmune globulin anti-COVID-19 [31]

Download (181KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies